To investigate the impact of MLLT3 on the prognosis of melanoma patients within a medium to short‐term period (within 10 years), we subsequently re‐analyzed the prognosis of high‐risk and low‐risk score groups, as well as the prognostic role of MLLT3 in melanoma patients. Here, MLLT3 is linked to melanoma.